Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
Date:3/5/2009

the write-down of goodwill of $599.4 million recorded in the third quarter of 2008, leaving no goodwill on our books as of December 31, 2008. - As of December 31, 2008, cash, short and long-term investments were $41.4 million and net debt was $535.2 million.

Significant Recent Developments

New Senior Secured Credit Facilities. On March 2, 2009 we announced that we had completed a financing transaction with Wells Fargo Foothill, LLC. The financing includes a delayed draw secured term loan facility of up to $10 million, and a secured revolving credit facility with a borrowing base derived from the value of certain of the Company's finished goods inventory and accounts receivable, providing up to an additional $22.5 million in available credit, subject to certain terms and conditions. Any borrowings outstanding under the term loan and revolving credit facility bear interest ranging from LIBOR + 3.25% to LIBOR +3.75%, with a minimum Base LIBOR Rate of 2.25%. The term loan and the revolving credit facility include certain covenants and restrictions with respect to our operations, require us to maintain certain levels of Adjusted EBITDA and interest coverage ratios, among other terms and conditions, and are secured by the assets of the Company and its Canadian and U.S. subsidiaries. The purpose of the financings is to provide additional liquidity and capital resources for working capital and general corporate purposes.

Financial and Strategic Alternatives Process. During approximately the last eight calendar quarters, our royalty revenue has declined significantly, primarily due to lower than expected royalties derived from sales by our partner Boston Scientific Corporation ("BSC") of TAXUS(R) coronary stent systems. This decline in royalty revenue has significantly impacted our ability to fund our operations and service our debt obligations, and has impacted our liquidity position. During
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
2. Angiotech Pharmaceuticals announces time change of conference call and webcast
3. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
4. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
5. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
6. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
7. Angiotech wins before the UK House of Lords
8. Angiotech to Establish Separate Operating and Royalty Businesses
9. Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
10. Angiotech announces market launch of Quill(TM) SRS MONODERM(TM)
11. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Texas , Jan. 14, 2014 The ... and research medicinal plants and therapeutic derivatives thereof ... health professionals, and researchers about the challenges of ... http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The Society ...
(Date:1/14/2014)... 2014 iLab Solutions, the leader in core ... Director of Product Strategy. In this role, Michelle will work ... to guide in the development of iLab products. Her main ... possible benefit to the scientific community by offering the most ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation ... developing and commercializing innovative therapies addressing major unmet ... it received the Notice of Allowance from the ... unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment ...
(Date:1/14/2014)... OTTAWA, Ontario , Jan. 14, 2014   Kinaxis ®, ... ( SCM ) and sales and operations planning ( S&OP ... the Biomanufacturing Summit , which will be held at ...  At the conference, join Kinaxis customer Elisabeth Kaszas , ...
Breaking Biology Technology:World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... 13 Accuri Cytometers, Inc. today announced the completion ... financing included current investors Fidelity Biosciences, Flagship Ventures, Baird ... InvestMichigan! Program co-managed by Credit Suisse. Accuri will ... provide additional working and growth capital to support the ...
... University a network of tiny sensors as small as ... determined intruder. Scattered outdoors on rocks, fence posts and ... dewdrops are a completely new and cost-effective system for safeguarding ... and his Tel Aviv University Faculty of Engineering team drew ...
... SAN DIEGO, July 10 David Koos, Chairman and CEO ... BMSN), today said that he believes that stem cell cord ... The Bio-Matrix CEO stated that hospitals throughout the world ... banks. "Hospitals from the U.S. to India are naturally ...
Cached Biology Technology:Accuri Cytometers Completes $4 Million Series D Financing 2Accuri Cytometers Completes $4 Million Series D Financing 3Accuri Cytometers Completes $4 Million Series D Financing 4Accuri Cytometers Completes $4 Million Series D Financing 5Intruder alert: Tel Aviv University's 'Smart Dew' will find you! 2Stem Cell Cord Blood 'Banking' Is Huge Global Business for Hospitals, Says CEO of Bio-Matrix Scientific Group Inc. 2
(Date:4/23/2014)... newly coined term for novels and films which focus on ... Copenhagen shows how these fictions serve as a mental laboratory ... change and imagine other living conditions. , "Global warming ... atmosphere; it is also a cultural phenomenon in which meaning ... films we see. And there are so many of them ...
(Date:4/23/2014)... HOUSTON, April 23, 2014 A biomedical engineer at ... highly innovative technology to make blood transfusions safer. His ... the National Institutes of Health (NIH). , Blood ... one of modern medicine,s absolute necessities. Without them, for ... mean transfusions are perfect, however. There,s strong evidence that ...
(Date:4/22/2014)... to behave at the dinner tablecut up their food and ... Eating Behaviors , found that when 6-10 year old children ... such as drumsticks, whole apples, or corn on the cob ... cut. "They were twice as likely to disobey adults ... Professor and Director of the Cornell Food and Brand Lab. ...
Breaking Biology News(10 mins):Fiction prepares us for a world changed by global warming 2Fiction prepares us for a world changed by global warming 3UH biomedical engineer works to make blood transfusions safer 2UH biomedical engineer works to make blood transfusions safer 3Biting vs. chewing 2
... have determined that most types of melanoma cells can ... form of skin cancer does not conform to the ... the researchers found that melanoma tumor cells can change ... making the malignant cells a stealthy, shape-shifting target for ...
... of California, San Diego NanoEngineers won a grant from ... tools to manufacture biodegradable frames around which heart tissues ... methods for growing tissues that mimic nature,s fine-grained details, ... grow replacement cardiac tissues for people who have suffered ...
... Elsevier, the leading publisher of scientific, technical and ... eBook collections available for advance purchase and to be ... The 2011 offerings total 439 titles spread across 24 ... between January 1 and December 31, 2011. ...
Cached Biology News:More evidence that melanoma does not conform to the cancer stem cell model 2More evidence that melanoma does not conform to the cancer stem cell model 3Nanoengineers aim to grow tissues with functional blood vessels 2Nanoengineers aim to grow tissues with functional blood vessels 3Elsevier announces the SciVerse ScienceDirect eBooks collection 2011 frontlist 2
... adapter allows the Thermo-Fast® ... AB-1000) PCR plates to ... ABI PRISM® 3700 capillary ... for information on the ...
Spectrolyse (pL) PAI kit is a two-stage indirect enzymatic assay for the quantitative determination of Plasminogen Activator Inhibitor (PAI-1) activity in plasma. Sample Type: plasma...
Rabbit anti-CRSP1 (TRAP220), Polyclonal Antibody, Unconjugated Applications: Immunohistochemistry - 1:100 - 1:500...
... White lyophilized solid. PROTECT FROM LIGHT. PACKAGED ... of γ-secretase. Equipotently inhibits the release of ... 2.6 μM) and Aβ x-42 (ED ... cells stably transfected with the Amyloid Precursor ...
Biology Products: